Ernexa Therapeutics Inc. Common Stock
$3.91
-$0.17 (-4.17%)
$3.84Day Range$4.16
Key Statistics
Market Cap
$4.56M
Shares Outstanding
1.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 26, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$4.01
Day High
$4.16
Day Low
$3.84
Volume
22.6K
VWAP
$3.95
Prev Close
$4.08
Transactions
--
Acc. Volume
--
About Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
PHARMACEUTICAL PREPARATIONSSIC 28345 employees1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141(617) 798-6700IPO Mar 26, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000748592
- Composite FIGI
- BBG000CX5677
- Share Class FIGI
- BBG001S74KP5
- Ticker Root
- ERNA
- SIC Code
- 2834
About Ernexa Therapeutics Inc. Common Stock (ERNA) Stock
Ernexa Therapeutics Inc. Common Stock (ERNA) closed the 2026-09-16 session at $3.91, down 4.17% versus the previous close (-0.17). The stock opened at $4.01 and traded between $3.84 and $4.16 during that session. Session trading volume was 23K shares. The volume-weighted average price (VWAP) is $3.95.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Ernexa Therapeutics Inc. Common Stock has a market capitalization of $4.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ERNA is listed on the XNAS exchange. The company employs approximately 5 people. Ernexa Therapeutics Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2021-03-26.
On this page you can find market ERNA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.